The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Chugai to Transfer Japan Rights for 3 Topical Maxacalcitol Products to Maruho
Chugai Pharmaceutical will transfer its Japan rights for three dermatological products containing maxacalcitol to Maruho on December 1, 2019, the two companies said on January 30. The three agents are Oxarol Ointment and Lotion for the treatment of keratosis including…
To read the full story
Related Article
- Chugai to Divest Oxarol Injection to LTL in Japan
August 29, 2024
- Chugai Completes Transfer of 3 Dermatology Products to Maruho
December 3, 2019
BUSINESS
- Cyto-Facto Expands CPC Footprint to Win Multiple Cell Therapy Contracts
December 24, 2025
- Shionogi, Salubritas Tie Up on Hair Cell Regeneration R&D for Hearing Loss
December 24, 2025
- Guardant360 Approved in Japan as CDx for Lilly’s Inluriyo
December 24, 2025
- Meiji Pharma Sets Up Singapore Unit to Bolster ASEAN Push
December 24, 2025
- Santen Releases VKC Eye Drop Verkazia in China
December 24, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…